UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K
Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): January 8, 2018

IOVANCE BIOTHERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware	
(State of Incorporation)	
001-36860	**75-3254381**
Commission File Number	**(I.R.S. Employer Identification No.)**
999 Skyway Road, Suite 150 **San Carlos, California**	**94070**
(Address of Principal Executive Offices)	**(Zip Code)**

(650) 260-7120
(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

Iovance Biotherapeutics, Inc. (the "Company") from time to time makes presentations at healthcare conferences and to analysts, current stockholders, and others. A copy of the Company's presentation that it intends to use during January 2018 is furnished as Exhibit 99.1 to this current report on Form 8-K and incorporated by reference herein.

On December 15, 2017, a purported shareholder derivative complaint, *Kevin Fong v. Manish Singh, et al.* (C.A. No. 17-1806), was filed against the Company, as nominal defendant, and certain of the Company's current and former officers and directors, and others, as defendants, in the U.S. District Court for the District of Delaware. The complaint alleges breaches of fiduciary duties, unjust enrichment, and violations of Section 14(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder arising from the Securities and Exchange Commission's investigation in the *In the Matter of Certain Stock Promotions* matter and the Company's April 10, 2017 settlement thereof, and seeks unspecified damages on behalf of the Company and injunctive relief.

The Company intends to vigorously defend against the foregoing complaint. Based on the very early stage of the litigation, it is not possible to estimate the amount or range of possible loss that might result from an adverse judgment or a settlement of the matter.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Iovance Biotherapeutics, Inc., Corporate Presentation - January 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 8, 2018

IOVANCE BIOTHERAPEUTICS, INC.

By: /s/ MARIA FARDIS
Maria Fardis, Chief Executive Officer

Exhibit 99.1


IOVANCE
BIOTHERAPEUTICS
ADVANCING IMMUNO-ONCOLOGY
Corporate Presentation
January 2018
© 2018, Iovance Biotherapeutics, Inc.

Forward-Looking Statements

This presentation contains forward-looking statements reflecting management's current beliefs and expectations. These forward looking statements can be identified with words such as "expects", "plans", "projects", "potential", "suggests", "may", or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this presentation include statements regarding (i) the success and timing of our product development activities and clinical trials, (ii) our ability, and the ability of our commercial partners, to manufacture, process and deliver our product candidates and to further improve on the manufacturing process, (iii) the size of the potential markets for our product candidates, (iv) our ability to develop next generation TIL and other more effective and efficient therapeutics, (v) our ability to maintain our collaborations and other relationships with third parties, (vi) our ability to attract and retain key management and scientific personnel, (vii) our ability to obtain and maintain intellectual property protection for our product candidates, (viii) our ability to compete with other therapeutics that target the same indications as our product candidates, and (ix) our ability to achieve our manufacturing, clinical, regulatory, and other key milestones, including the progression of third-party sponsored studies, which may require additional clinical trials and manufacturing development.

For more detailed information about the risks and uncertainties that could cause actual results to differ materially from those implied by, or anticipated in, these forward-looking statements, please refer to the Risk Factors section of the Company's Annual Report on Form 10-K and subsequent updates that may be contained in the Company's Quarterly Reports on Form 10-Q and current reports on Form 8-K on file with the SEC. Forward-looking statements speak only as to the date they are made. Except as required by law, the Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward looking statements are made. This presentation does not constitute an offer to sell or buy securities, and no offer or sale will be made in any state or jurisdiction in which such offer or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

TIL Therapy is a Proven Treatment for Solid Tumors

- Developing and commercializing tumor infiltrating lymphocyte (TIL) therapies as a platform for treatment of cancers
- Leveraging and enhancing the utility of TIL therapy as demonstrated by Dr. Steven Rosenberg at the National Cancer Institute (NCI) for metastatic melanoma:
  - 56% ORR[1]
  - 24% CR rate in 101 metastatic melanoma patients, durable CRs[2]

ESTIMATED NEW CASES 2017[3]

ESTIMATED DEATHS 2017[3]

[1] Rosenberg, S. A., et al. Clinical Cancer Research, 2011, 17, 4550.
[2] Goff, S. L. et al. Journal of Clinical Oncology, 2016, 34(20), 2389-2397.
[3] https://seer.cancer.gov/statfacts/html/all.html
Data from third parties may not be representative of Iovance's data.

IOVANCE BIOTHERAPEUTICS

Iovance Corporate Highlights

- **Clinical Development:**
  - Iovance pipeline of three ongoing and one upcoming company-sponsored trials
    - **Melanoma**
      - C-144-01 Phase 2 trial of LN-144 in metastatic melanoma with positive responses seen in heavily pre-treated patients[1]
        - **Orphan Drug** Designation in malignant melanoma stages IIB-IV
        - **Fast Track** Designation for advanced melanoma
    - **Head and neck**
      - LN-145 Phase 2 trial (C-145-03) enrolling in the U.S.
    - **Cervical**
      - LN-145 Phase 2 trial (C-145-04) enrolling in the U.S.
    - **NSCLC**
      - LN-145 Phase 2 trial expected to initiate 1H 2018

- **Manufacturing:**
  - TIL clinical and commercial manufacturing capabilities fully in place in U.S.
  - 22 day Gen 2 manufacturing process for TIL selected for all trials

- **Collaborators:**
  - TIL pipeline collaborations and partnerships with NIH/NCI, Moffitt Cancer Center, MD Anderson Cancer Center, MedImmune / AstraZeneca, Ohio State University

[1] Sarnaik, A. ASCO, 2017, 140. Sarnaik, A. SITC, 2017.

IOVANCE BIOTHERAPEUTICS

Iovance Clinical Pipeline

INDICATION	REGIMEN	N	PARTNER	PRECLINICAL	PHASE 1	PHASE 2
Melanoma	TIL LN-144	60	—			Enrolling
Cervical Cancer	TIL LN-145	47	—			Enrolling
Head & Neck Cancer	TIL LN-145	47	—			Enrolling
Non-Small Cell Lung Cancer	TIL LN-145 vs TIL LN-145 + durvalumab	24	MedImmune			Phase 2 trials to initiate in 2018

IOVANCE BIOTHERAPEUTICS

Iovance Collaboration Pipeline

INDICATION	REGIMEN	N	PARTNER	PRECLINICAL	PHASE 1	PHASE 2
Melanoma	Combination TIL ± TBI	101	NIH			Trial completed, 54% ORR, 24% CR
Melanoma	Combination TIL + Yervoy		MOFFITT			Trial completed, publishing results
Melanoma	Combination TIL + Keytruda	170	NIH			Enrolling
Melanoma	Combination TIL + Opdivo	12	MOFFITT		Enrolling	
Ocular (Uveal) Melanoma	TIL	23	NIH			
Glioblastoma	TIL		Karolinska Institutet			
Pancreatic Cancer	TIL		Karolinska Institutet			
Ovarian, Sarcomas, Pancreatic	TIL		MD Anderson Cancer Network			Phase 2 trials to initiate in 2018
Non-small cell lung cancer	Combination TIL + Opdivo	18	MOFFITT		Enrolling	

IOVANCE BIOTHERAPEUTICS

TIL Therapy Overview

TIL Therapy Elicits a Highly Individualized, Specific and Potent Attack Against Solid Tumors

- Leverages and enhances the body's natural defense against cancer using a patient's own TIL
- Polyclonal and can recognize multiple neoantigens
  - Solid tumors are heterogeneous
- Durable response with single treatment:
  - Potential to establish immunological memory, requiring no additional maintenance therapy after infusion
  - Responses seen both in treatment naïve and refractory melanoma patients who have failed other options, including checkpoint inhibitors
  - Complete responses observed at 54 months in cervical cancer patient



TIL Therapy Process



- EXCISION: Patient's TIL are removed from suppressive tumor microenvironment (via surgical resection of a lesion)
- EXTRACTION: Tumor is fragmented and placed in media for TIL to leave the tumor and enter media
- EXPANSION: TIL expanded exponentially *ex vivo* to yield 10^9 – 10^{11} TIL
- PREPARATION: Patient receives non-myeloablative lymphodepletion to eliminate potentially suppressive tumor microenvironment and maximize engraftment and potency of TIL therapy:
  - cyclophosphamide: 60 mg/kg x 2 doses
  - fludarabine: 25 mg/m^2 x 5 doses
- INFUSION: Patient is infused with their expanded TIL and IL-2 (600,000 IU/kg, up to 6 doses) to promote activation, proliferation and anti-tumor cytolytic activity of TIL

IOVANCE BIOTHERAPEUTICS

Competitive Advantages of TIL in Solid Tumors

CHECKPOINTS	TCR	CAR-T (LIQUID TUMORS)	TIL (SOLID TUMORS)
Utility in several solid tumors	Few solid tumors treated so far	No examples of successful utility in solid tumors	Available data in melanoma and cervical cancers
Long maintenance period	One-time treatment	One-time treatment	One-time treatment
No genetic modification	Genetic modification	Genetic modification	No genetic modification
Potential Long-term irreversible toxicities	Potential on-target, off-tissue effects	Potentially immunogenic: cytokine release syndrome	Minimal chance of unpredicted on-target, off-tissue effects found to date
Target multiple tumor antigens	Target only single tumor antigen	Mainly target only single/ surface tumor antigen	Target multiple tumor antigens
Off-the-shelf	Autologous	Autologous	Autologous
No HLA restriction	HLA restriction	No HLA restriction	No HLA restriction

- TIL cells target a diverse array of cancer antigens; this approach represents a highly differentiated, customized, and targeted immunotherapy

IOVANCE BIOTHERAPEUTICS

NCI Study Survival Benefit in Second and Third Line Patients



IN SECOND AND THIRD LINE MELANOMA (no prior anti-PD-1)

ORR 56%

CR 22%

Rosenberg, S.A., et al. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. *Clinical Cancer Research*, 17(13), 4550-4557.
Data from third parties may not be representative of Iovance's data.
Abbreviations: CR, complete response; ORR, objective response rate.
Data from third parties may not be representative of Iovance's data

IOVANCE BIOTHERAPEUTICS

Manufacturing

Iovance Cryopreserved 22 Day TIL Manufacturing Process



IOVANCE BIOTHERAPEUTICS

TIL Therapy Manufacturing

- Clinical and commercial manufacturing capabilities are in place in the US and EU
  - US: Lonza, WuXi (multiple locations), Moffitt
  - EU: LonzaNL (formerly PharmaCell)
- Shorter Generation 2 manufacturing process has been selected for all current and future Iovance studies (all protocols amended)
  - Shortens the time patients will receive their TIL product
  - Allows flexibility in scheduling of treatment dosing at infusion center
  - Reduces cost of manufacturing by ~35% vs Gen 1
- WuXi Phase 3 clinical and commercial suite is being used for manufacturing the Gen 2 product

IOVANCE BIOTHERAPEUTICS

Cell Orchestration Platform (TrakCel Collaboration)

Logistics of Each Patient's Sample and TIL Therapy

An automated process integrating scheduling, capacity and logistics throughout the supply chain: Part 11 compliant, improves communication across stakeholders

1. EXCISE
2. EXTRACT
3. EXPAND
4. PREPARE & INFUSE



Legend:
- Clinic
- Iovance CMO GMP Facility

IOVANCE BIOTHERAPEUTICS

Melanoma

Iovance C-144-01 Phase 2 Trial in Metastatic Melanoma

Phase 2, multicenter study to assess the efficacy and safety of autologous Tumor Infiltrating Lymphocytes (LN-144) for treatment of patients with metastatic melanoma (NCT02360579)



Key Inclusion Criteria:

- Measurable metastatic melanoma and ≥ 1 lesion resectable for TIL generation
- Progression on at least one prior line of systemic therapy including immune checkpoint inhibitor
- Age ≥ 18
- ECOG PS 0-1

Treatment Cohorts:

1. Non-cryopreserved LN-144 product
2. Cryopreserved LN-144 product
3. Retreatment with LN-144 for patients without response or who progress after initial response

Endpoints:

- Primary: Efficacy defined as ORR
- Secondary: Safety and efficacy

IOVANCE BIOTHERAPEUTICS

COHORT 2

Iovance C-144-01 Patient Characteristics:
Interim Data as of Dec. 2017 Data Cut

CHARACTERISTIC	Cohort 2 N=17, (%)
Gender, n (%)	
Male	8 (47)
Female	9 (53)
Age	
Median	54
Min, Max	35, 66
Prior therapies, n (%)	
Mean # prior systemic therapies	3.6
Anti-CTLA-4	15 (88)
Anti-PD-1	16 (94)
Target Lesion Sum of Diameter (mm)	
Mean (SD)	140 (93)
Min, Max	38, 342

CHARACTERISTIC	Cohort 2 N=17, (%)
Baseline ECOG score, n (%)	
0	11 (65)
1	6 (35)
BRAF Status, n (%)	
Mutated	5 (29)
Wild Type	9 (53)
Unknown	3 (18)
Baseline LDH (U/L)	
1-2 times ULN	8 (47)
> 2 times ULN	2 (12)
Number of Target & Non-Target Lesions (at Base Line)	
>3	12 (71)
Mean	5.9

* Database cut off of 1 Dec 2017

Cohort 2 has:

- 3.6 median prior therapies
- High tumor burden at baseline as reflected by 140 mm sum of diameters for target lesions

IOVANCE BIOTHERAPEUTICS

COHORT 2

Iovance C-144-01 Safety:
Treatment Emergent Adverse Events (≥ 30%)

PREFERRED TERM	Cohort 2 (N=17) Any Grade n (%)	Grade 3/4 n (%)	Grade 5 n (%)
Number of patients reporting at least one Treatment-Emergent AE	16 (94.1)	16 (94.1)	0
Pyrexia	13 (76.5)	1 (5.9)	0
Anaemia	11 (64.7)	10 (58.8)	0
Neutrophil count decreased	10 (58.8)	10 (58.8)	0
Platelet count decreased	10 (58.8)	8 (47.1)	0
Febrile neutropenia	10 (58.8)	8 (47.1)	0
Fatigue	10 (58.8)	0	0
Chills	9 (52.9)	1 (5.9)	0
Nausea	9 (52.9)	0	0
White blood cell count decreased	8 (47.1)	8 (47.1)	0
Lymphocyte count decreased	6 (35.3)	6 (35.3)	0
Diarrhoea	6 (35.3)	0	0
Decreased appetite	6 (35.3)	0	0

Notes: Patients with multiple events for a given preferred term are counted only once using the maximum grade under each preferred term. Treatment-Emergent Adverse Events refer to all AEs starting on or after the first dose date of pre-treatment chemotherapy (Fludarabine and Cyclophosphamide) up to the last dose of IL-2 + 30 days.

IOVANCE BIOTHERAPEUTICS

COHORT 2

Time to Response for Evaluable Patients (SD or Better)

- DCR is: 80%
- Time to response is similar to Cohort 1



Of 10 patients in Efficacy Set, one patient (Patient 10) is not evaluable (NE) due to melanoma-related death prior to first tumor assessment not represented on figure.

IOVANCE BIOTHERAPEUTICS

COHORT 2

Iovance C-144-01 Efficacy

- Mean number of TIL cells infused: 34×10^9
- Median number of IL-2 doses administered was 4.5
- Patients with BRAF mutation responded as well as patients with wild type BRAF



One patient (Patient 10) had passed away prior to the first assessment (still considered in the Efficacy Set).
* Refers to patients with BRAF mutation

Abbreviations: PR, partial response; SD, stable disease, PD, progressive disease

IOVANCE BIOTHERAPEUTICS

COHORT 2

Iovance C-144-01 Efficacy: Evaluable Patient Data

- All efficacy-evaluable patients had received an anti-PD-1 and anti-CTLA-4 checkpoint inhibitor

RESPONSE	PATIENTS, N=10 n (%)
Objective Response Rate	**4 (40%)**
Disease Control Rate	8 (80%)
Partial Response	4 (40%)
Stable Disease	4 (40%)
Progressive Disease	1 (10%)
Non-Evaluable*	1 (10%)

1 Dec 2017 Data Cut
* NE due to not reaching first assessment.

IOVANCE BIOTHERAPEUTICS

CT Scan for Patient with PR



TL1: Lt low. quad. abdom. - BL: 8.8 cm / 18 wk: 3.7 cm

TL2: Lt uppr quad abdom. - BL: 5.2 cm / 18 wk: 0 cm

TL3: Lt renal – BL: 4.1 cm / 18 wk: 2.1 cm

TL5: Rt femoral LN - 4 cm (short axis) / 18 wk: 2.3 cm

IOVANCE BIOTHERAPEUTICS

Head & Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

HNSCC Cancer Facts[1,2]

765k **New Cases WW** each year

303k **Deaths WW** each year

63k **Diagnoses in U.S.** each year

13k **Deaths in U.S.** each year

HNSCC
Well-suited for immunotherapy

ORR 13-16%
For population receiving immunotherapy (e.g, PD-1 inhibitors)

TIL
Prognostic value in HPV^{+} & HPV^{-} tumor specimens

Abbreviations: HPV, human papillomavirus infection; OPC, oropharyngeal cancer; ORR, objective response rate; TIL, tumor infiltrating lymphocytes.

[1] Global Burden of Disease Cancer Collaboration, Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524

2 https://seer.cancer.gov/statfacts/html/oralcav.html and https://seer.cancer.gov/statfacts/html/laryn.html

IOVANCE BIOTHERAPEUTICS

CURRENTLY ENROLLING

Iovance C-145-03 Phase 2 Trial in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 study to evaluate the efficacy and safety of autologous Tumor Infiltrating Lymphocytes (LN-145) for the treatment of patients with recurrent metastatic squamous cell carcinoma of the head and neck (NCT03083873)



- N=47; Simon's two-stage design triggered
- LN-145: protocol was amended to continue enrollment with Gen 2 product
- Preliminary data anticipated at an upcoming scientific conference in 2018

Key Inclusion Criteria:

- Measurable metastatic disease and ≥ 1 lesion resectable for TIL generation
- Relapsed or refractory recurrent metastatic squamous cell carcinoma of the head and neck and have received at least one prior systemic therapy
- Age ≥ 18
- ECOG PS 0-1

Endpoints:

- Primary: Efficacy defined as ORR
- Secondary: Safety and efficacy

IOVANCE BIOTHERAPEUTICS

Cervical Cancer

NCI Cervical Cancer and TIL Treatment Data

	PATIENTS (%)	DURATION (MONTHS)
Total	9 (100)	
PR	1 (11)	3
CR	2 (22)	54+, 46+



Stevanovic, et al. Complete Regression of Metastatic Cervical Cancer After Treatment with Human Papillomavirus-Targeted Tumor-Infiltrating T Cells, *J Clin Oncol* 2015, 33 (14), 1543.
Hinrichs, et al. HPV-targeted Tumor-Infiltrating Lymphocytes for Cervical Cancer, *J Clin Oncol*, 2014, 23, 5s.
Stevanovic et al., *Science*, 2017, (356), 200.
This type of response may not be representative of all patients.

IOVANCE BIOTHERAPEUTICS

Iovance C-145-04 Phase 2 Trial in Recurrent, Metastatic or Persistent Cervical Carcinoma

Phase 2, multicenter study to evaluate the efficacy and safety of autologous Tumor Infiltrating Lymphocytes (LN-145) in patients with recurrent, metastatic or persistent cervical carcinoma (NCT03108495)



N=47; Simon's two-stage design

LN-145, protocol was amended to continue enrollment with Gen 2 product

Study is expected to begin enrolling in Europe in 2018

Key Inclusion Criteria:

- Measurable recurrent, persistent, or metastatic disease and ≥ 1 lesion resectable for TIL generation
- At least one prior systemic therapy and either progressed or had no response on such therapy
- Age ≥ 18
- ECOG PS 0-1

Endpoints:

- Primary: Efficacy defined as ORR
- Secondary: Safety and efficacy

IOVANCE BIOTHERAPEUTICS

Non-Small Cell Lung Cancer

Market Opportunity for TIL Therapy in US

INDICATION	NEW CASES[1]	DEATHS[1]
Melanoma	87,110	9,730
Cervix Uteri	12,820	4,210
Oral Cavity, Pharynx & Larynx	63,030	13,360
Lung & Bronchus	222,500	155,870
Bladder	79,030	16,870
Breast	252,710	40,610
Pancreatic	53,670	43,090
Brain & Other Nervous System	23,800	16,700

LUNG CANCER

222K

New cases in 2017

5YR SURVIVAL RATE[2]

<20% for NSCLC

[1] https://seer.cancer.gov
[2] https://seer.cancer.gov/statfacts/html/lungb.html

IOVANCE BIOTHERAPEUTICS

Ongoing Collaborations and Partnerships

Two ongoing trials in Non-Small Cell Lung Cancer (NSCLC)

Moffitt Cancer Center sponsored trial

- TIL + anti-PD-1, nivolumab (Opdivo®):
- An Investigator Initiated Trial (IIT), Phase 1 study in 18 advanced NSCLC patients[1]

MOFFITT CANCER CENTER

STAND UP TO CANCER

Iovance sponsored trial in collaboration with MedImmune / AstraZeneca

- TIL +/- anti-PD-L1, durvalumab:
- Iovance-sponsored, Phase 2, two-cohort clinical trial to anti-PD-1/PD-L1 naïve NSCLC patients to start in 1H 2018

MedImmune

AstraZeneca

[1] A Stand Up to Cancer (SU2C) supported clinical trial. Additional collaborators include Bristol-Myers Squibb and Prometheus Inc.

IOVANCE BIOTHERAPEUTICS

NSCLC Phase 2 Study

Expected start: 1H 2018

A Phase 2 Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and in Combination with Anti-PD-L1 Inhibitor Durvalumab (MEDI4736) in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)



Key Inclusion Criteria:

- Histologically and/or cytologically confirmed diagnosis of Stage III or Stage IV NSCLC
- ≥ 1 lesion resectable for TIL generation

Key Exclusion Criteria:

- Prior anti-PD-1 or anti PD-L1 use

Endpoints:

- **Primary:** Efficacy (ORR) and safety
- **Secondary:** Efficacy

MedImmune

IOVANCE BIOTHERAPEUTICS

Collaborations

MD Anderson Collaboration

- Iovance has a collaboration with MD Anderson involving:
  - Preclinical research in expanding understanding of TIL
  - Two clinical studies:
    - LN-145 being provided by Iovance; expect first patient dosed in 1H 2018
      - Indications: sarcoma, platinum-resistant ovarian cancer
    - TIL being manufactured by MDA manufacturing method (co-stimulants used *ex vivo* to expand growth of TIL)
  - Access to certain IP related to the method of manufacturing from MDA

MD Anderson Cancer Network™

Corporate

Financial Summary

AS OF SEPTEMBER 30, 2017	IN MILLIONS
Common shares outstanding	72.0
Preferred shares	8.8[1]
Warrants/options/RSU's	13.2
Cash	$163
Debt	$0

[1] Preferred shares are shown on an as-converted basis.

Summary of Recent Accomplishments
Investigating Power of TIL Platform for Multiple Indications

- Broad Clinical Program:
  - Updated data in melanoma trial with preliminary results indicating clinically meaningful benefit in patients with multiply relapsed/refractory disease
  - Cervical and head and neck studies are progressing
  - TIL will be investigated in NSCLC
  - Moving to earlier line of therapy for TIL
  - MDA collaboration is in start up for sarcomas and ovarian cancer
- Streamlining the Manufacturing:
  - Capacity established in U.S. and Europe
  - Development of shorter duration Gen 2 for all future TIL therapy development and commercialization
- Building the IP:
  - A broad portfolio of immuno-oncology patent applications including coverage for Gen 2 manufacturing

IOVANCE BIOTHERAPEUTICS

Key Anticipated 2018 Milestones

MANUFACTURING

- Transition all trials over to Gen 2 manufacturing process
- Optimization of the process in anticipation of commercialization
- Start up in manufacturing and clinical trials in Europe

CLINICAL

- Continue enrollment into the melanoma program
- Continue to advance head & neck, cervical, and NSCLC
- Pursue new indications
- Actively move TIL therapy to earlier line of treatment
- Present data from melanoma and at least one other indication at 2018 medical meetings

REGULATORY

- FDA interaction to define the registration path for LN-144
- Activate melanoma and cervical studies in Europe in 1H 2018

PARTNERSHIPS

- Partner with our suppliers and vendors
- Continue collaborating with new clinical sites and hospitals to assure preparation for commercialization

IOVANCE BIOTHERAPEUTICS

ADVANCING IMMUNO-ONCOLOGY

Thank you